Menu
Back to User profile » Dr Khaled Elsayes
Papers published by Dr Khaled Elsayes:
Enhancement Pattern Mapping for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis
Nikzad N, Fuentes DT, Roach M, Chowdhury T, Cagley M, Badawy M, Elkhesen A, Hassan M, Elsayes KM, Beretta L, Koay EJ, Jalal PK
Journal of Hepatocellular Carcinoma 2024, 11:595-606
Published Date: 20 March 2024
The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
Awiwi MO, Elsayes KM, Mohamed YI, Altameemi L, Gjoni M, Irshad OM, Sayed Ahmed A, Kaseb AO, Salem U
Journal of Hepatocellular Carcinoma 2022, 9:913-927
Published Date: 30 August 2022
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma
Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A
Journal of Hepatocellular Carcinoma 2021, 8:1129-1145
Published Date: 9 September 2021
Value of Follow-Up Chest Computed Tomography in the Surveillance of Patients with Hepatocellular Carcinoma
Moawad AW, Elsayes KM, Benamar F, Rao K, Sun J, Szklaruk J
Journal of Hepatocellular Carcinoma 2020, 7:331-335
Published Date: 18 November 2020
Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging
Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM
Journal of Hepatocellular Carcinoma 2020, 7:77-89
Published Date: 23 April 2020
LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance
Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, Marks RM, Kamaya A, Do RKG, Kono Y, Fowler KJ, Tang A, Bashir MR, Hecht EM, Jambhekar K, Lyshchik A, Rodgers SK, Heiken JP, Kohli M, Fetzer DT, Wilson SR, Kassam Z, Mendiratta-Lala M, Singal AG, Lim CS, Cruite I, Lee J, Ash R, Mitchell DG, McInnes MDF, Sirlin CB
Journal of Hepatocellular Carcinoma 2019, 6:49-69
Published Date: 5 February 2019
Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance
Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, Hazle JD, Elsayes KM
Journal of Hepatocellular Carcinoma 2018, 5:61-73
Published Date: 27 June 2018
Liver Imaging Reporting and Data System: an expert consensus statement
Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, Mitchell DG, Do RK, Fowler KJ, Chernyak V, Sirlin CB
Journal of Hepatocellular Carcinoma 2017, 4:29-39
Published Date: 17 February 2017
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC
OncoTargets and Therapy 2016, 9:773-780
Published Date: 15 February 2016
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO
Journal of Hepatocellular Carcinoma 2016, 3:1-7
Published Date: 5 February 2016